Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism

Cardiovascular Research

Volumn 97, Issue 1, 2013, Pages 23-32

  Danielsson, Christian ^a   Brask, Johan ^b   Sköld, Anna Carin ^c   Genead, Rami ^a   Andersson, Agneta ^a   Andersson, Ulf ^c   Stockling, Kenneth ^c   Pehrson, Rickard ^c   Grinnemo, Karl Henrik ^a   Salari, Sajjad ^b   Hellmold, Heike ^c   Danielsson, Bengt ^d,e   Sylvén, Christer ^a   Elinder, Fredrik ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d Pharmanet Development Group   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Arrhythmia; Embryo; K channel; Long QT syndrome; Teratogenicity

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; MESSENGER RNA; POTASSIUM CHANNEL;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATRIOVENTRICULAR BLOCK; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROCARDIOGRAM; ELECTROGRAPHY; EMBRYO; EMBRYO CELL; EMBRYO DEVELOPMENT; FETUS DEVELOPMENT; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MEASUREMENT; NONHUMAN; ORGANOGENESIS; PATCH CLAMP; PRIORITY JOURNAL; QT INTERVAL; RAT;

ACTION POTENTIALS; ANIMALS; ATRIOVENTRICULAR BLOCK; CELLS, CULTURED; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GESTATIONAL AGE; HEART DEFECTS, CONGENITAL; HUMANS; KCNQ1 POTASSIUM CHANNEL; KINETICS; LONG QT SYNDROME; MYOCYTES, CARDIAC; ORGANOGENESIS; PATCH-CLAMP TECHNIQUES; PIPERIDINES; POLYMERASE CHAIN REACTION; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; PYRIDINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RNA, MESSENGER; SPECIES SPECIFICITY; TERATOGENS;

EID: 84871798294     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs296     Document Type: Article

References (47)

1. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-187.
2. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL et al. Coassem-bly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996;384:80-83. (Pubitemid 26374592)
3. Abbott GW, Xu X, Roepke TK. Impact of ancillary subunits on ventricular repolariza-tion. J Electrocardiol 2007;40:S42-S46. (Pubitemid 350052063)
4. Webster G, Berul CI. Congenital long-QT syndromes: a clinical and genetic update from infancy through adulthood. Trends Cardiovasc Med 2008;18:216-224.
5. Ohno S, Toyoda F, Zankov DP, Yoshida H, Makiyama T, Tsuji K et al. Novel KCNE3 mutation reduces repolarizing potassium current and associated with long QT syndrome. Hum Mutat 2009;30:557-563.
6. Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol 2000;83:1-19. (Pubitemid 30352651)
7. ICH-S7B, S7B. The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. European Medicines Agency; 2005. http://www.ich.org/fileadmin/Public-Web-Site/ ICH- Products/Guidelines/Safety/S7B/Step4/S7B-Guideline.pdf (29 October 2010)
8. ICH-E14, E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs, 2005.
9. Webster WS, Brown-Woodman PD, Snow MD, Danielsson BR. Teratogenic potential of almokalant, dofetilide, and D-sotalol: drugs with potassium channel blocking activity. Teratology 1996;53:168-175. (Pubitemid 26190889)
10. Marks TA, Terry RD. Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology 1996;54:157-164. (Pubitemid 27042478)
11. Skold AC, Danielsson BR. Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol. Pharmacol Toxicol 2001;88:34-39. (Pubitemid 32113220)
12. Nilsson MF, Danielsson C, Skold AC, Johansson A, Blomgren B, Wilson J et al. Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs. Reprod Toxicol 2010;29:156-163.
13. Karlsson M, Danielsson BR, Nilsson MF, Danielsson C, Webster WS. New proposals for testing drugs with IKr-blocking activity to determine their teratogenic potential. Curr Pharm Des 2007;13:2979-2988. (Pubitemid 350130965)
14. Skold AC, Danielsson C, Linder B, Danielsson BR. Teratogenicity of the I(Kr)-blocker cisapride: relation to embryonic cardiac arrhythmia. Reprod Toxicol 2002;16:333-342. (Pubitemid 34982965)
15. Skold AC, Wellfelt K, Danielsson BR. Stage-specific skeletal and visceral defects of the I(Kr)-blocker almokalant: further evidence for teratogenicity via a hypoxia-related mechanism. Teratology 2001;64:292-300. (Pubitemid 33108085)
16. Wellfelt K, Skold AC, Wallin A, Danielsson BR. Teratogenicity of the class III antiar-rhythmic drug almokalant: role of hypoxia and reactive oxygen species. Reprod Toxicol 1999;13:93-101. (Pubitemid 29165840)
17. Ban Y, Konishi R, Kawana K, Nakatsuka T, Fujii T, Manson JM. Embryotoxic effects of L-691, 121, a class III antiarrhythmic agent, in rats. Arch Toxicol 1994;69:65-71. (Pubitemid 24367145)
18. Spence SG, Vetter C, Hoe CM. Effects of the class III antiarrhythmic, dofetilide (UK-68, 798) on the heart rate of midgestation rat embryos, in vitro. Teratology 1994;49:282-292. (Pubitemid 24137962)
19. Danielsson BR, Skold AC, Johansson A, Dillner B, Blomgren B. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol 2003;193:168-176. (Pubitemid 37476432)
20. Patterson AJ, Zhang L. Hypoxia and fetal heart development. Curr Mol Med 2010;10:653-666.
21. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
22. Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006;21:221-222. (Pubitemid 43294548)
23. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111-120.
24. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemio-logical studies. Birth Defects Res A Clin Mol Teratol 2010;88:159-170.
25. Kallen BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005;20:209-214. (Pubitemid 40725070)
26. Abrahamsson C, Palmer M, Ljung B, Duker G, Baarnhielm C, Carlsson L et al. Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc Res 1994;28:337-344. (Pubitemid 24131070)
27. Harrell MD, Harbi S, Hoffman JF, Zavadil J, Coetzee WA. Large-scale analysis of ion channel gene expression in the mouse heart during perinatal development. Physiol Genomics 2007;28:273-283. (Pubitemid 46708768)
28. Franco D, Demolombe S, Kupershmidt S, Dumaine R, Dominguez JN, Roden D et al. Divergent expression of delayed rectifier K(+) channel subunits during mouse heart development. Cardiovasc Res 2001;52:65-75. (Pubitemid 32835239)
29. Chun KR, Koenen M, Katus HA, Zehelein J. Expression of the IKr components KCNH2 (rERG) and KCNE2 (rMiRP1) during late rat heart development. Exp Mol Med 2004;36:367-371. (Pubitemid 39279533)
30. de Castro MP, Aranega A, Franco D. Protein distribution of Kcnq1, Kcnh2, and Kcne3 potassium channel subunits during mouse embryonic development. Anat Rec A Discov. Mol Cell Evol Biol 2006;288:304-315.
31. Davies MP, An RH, Doevendans P, Kubalak S, Chien KR, Kass RS. Developmental changes in ionic channel activity in the embryonic murine heart. Circ Res 1996;78:15-25. (Pubitemid 26004116)
32. Jezek K, Pucelik P, Sauer J, Bartak F. Basic electrophysiological parameters and frequency sensitivity of the ventricular myocardium of human embryos. Physiol Bohemoslov 1982;31:11-19. (Pubitemid 12105900)
33. Tuganowski W, Cekanski A. Electrical activity of a single fibre of the human embryonic heart. Pflugers Arch 1971;323:21-26.
34. Meyer T, Boven KH, Gunther E, Fejtl M. Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation. Drug Saf 2004;27:763-772. (Pubitemid 39243560)
35. Reppel M, Pillekamp F, Lu ZJ, Halbach M, Brockmeier K, Fleischmann BK et al. Micro-electrode arrays: a new tool to measure embryonic heart activity. J Electrocardiol 2004; 37(Suppl):104-109. (Pubitemid 39452876)
36. Halbach M, Egert U, Hescheler J, Banach K Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol Biochem 2003;13:271-284. (Pubitemid 37356733)
37. Yeung CK, Sommerhage F, Wrobel G, Law JK, Offenhausser A, Rudd JA et al. To establish a pharmacological experimental platform for the study of cardiac hypoxia using the microelectrode array. J Pharmacol Toxicol Methods 2009;59:146-152.
38. Stett A, Egert U, Guenther E, Hofmann F, Meyer T, Nisch W et al. Biological application of microelectrode arrays in drug discovery and basic research. Anal Bioanal Chem 2003;377:486-495. (Pubitemid 40877870)
39. Mannikko R, Pandey S, Larsson HP, Elinder F. Hysteresis in the voltage dependence of HCN channels: conversion between two modes affects pacemaker properties. J Gen Physiol 2005;125:305-326. (Pubitemid 40388311)
40. Zhang Y, Xiao J, Wang H, Luo X, Wang J, Villeneuve LR et al. Restoring depressed HERG K+ channel function as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits. Am J Physiol Heart Circ Physiol 2006;291:H1446-H1455. (Pubitemid 44343692)
41. Danielsson BR, Danielsson C, Nilsson MF. Embryonic cardiac arrhythmia and generation of reactive oxygen species: common teratogenic mechanism for IKr blocking drugs. Reprod Toxicol 2007;24:42-56. (Pubitemid 47042351)
42. Webster WS, Abela D. The effect of hypoxia in development. Birth Defects Res C Embryo Today 2007;81:215-228. (Pubitemid 350086248)
43. Roche M, Renauleaud C, Ballet V, Doubovetzky M, Guillon JM. The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability. J Pharmacol Toxicol Methods 2010;61:238-250.
44. Nalos L, Varkevisser R, Jonsson MK, Houtman MJ, Beekman JD, van der Nagel R et al. Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes. Br J Pharmacol 2012;165:467-478.
45. Einarson A, Choi J, Einarson TR, Koren G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J Obstet Gynaecol Can 2009;31:452-456.
46. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010;182:1031-1037.
47. Einarson A, Phillips E, Mawji F, D'Alimonte D, Schick B, Addis A et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998;15:523-525. (Pubitemid 29017981)